

## Conversion of <sup>99m</sup>technetium-pyrophosphate scintigraphy in a patient with hereditary ATTR amyloidosis: importance of repeat scanning

## Muzna Hussain ()<sup>1</sup>, Brett W. Sperry ()<sup>2</sup>, Mazen Hanna<sup>1</sup>, and Wael A. Jaber<sup>1</sup>\*

<sup>1</sup>Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart and Vascular Institute, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk J1-5, Cleveland, OH 44195, USA; and <sup>2</sup>Saint Luke's Mid America Heart Institute, Kansas City, MO 64111, USA

Received 12 August 2020; first decision 26 August 2020; accepted 16 September 2020; online publish-ahead-of-print 9 November 2020

A 73-year-old female with spinal stenosis, hypertension, and bilateral carpal tunnel syndrome underwent release surgery with tenosynovial biopsy demonstrating transthyretin (TTR) amyloid deposition. Genetic testing for TTR demonstrated Ala81Thr mutation consistent with hereditary amyloid transthyretin (ATTR amyloidosis).

Electrocardiogram was normal (Supplementary material online, *Figure S1A*), troponin T was <0.01 ng/mL, and N-terminal prohormone of brain natriuretic peptide (NT pro-BNP) was 101 pg/mL. Echocardiography revealed normal global longitudinal strain (GLS) with normal left ventricular (LV) size, no increased wall thickness,



<sup>\*</sup> Corresponding author. Tel: +1 216 444 8305, Email: jaberw@ccf.org

Handling Editor: Joseph Moutiris

<sup>©</sup> The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

and left ventricular ejection fraction (LVEF) 62% (Supplementary material online, *Figure S2A and B*). <sup>99m</sup>Technetium-pyrophosphate (<sup>99m</sup>Tc-PYP) showed no uptake on planar or single-photon emission computed tomography (SPECT) imaging and heart-to-contralateral ratio (H:CL) was <1.25 at 3 h (*Panels A and B*).

Cardiac magnetic resonance at 3 years revealed no gadolinium uptake with normal LV size (end-diastolic volume 84 mL), normal systolic function (LVEF 68%), normal T1 time, and extracellular volume (ECV) (*Panel C*). At 4 years, the patient remained asymptomatic. ECG was normal (Supplementary material online, *Figure S1B*), troponin T was <0.01 ng/mL, and NT pro-BNP was 119 pg/mL. Echocardiography showed no changes (*Panel D* and Supplementary material online, *Figure S2C*). Repeat <sup>99m</sup>Tc-PYP demonstrated grade 3 uptake on SPECT and planar imaging and H:CL of 2.40, consistent with ATTR cardiac amyloidosis (*Panels E and F*).

To the best of our knowledge, this is the first reported case of conversion of negative  $^{99m}\mbox{Tc-PYP}$  to positive  $^{99m}\mbox{Tc-PYP}$  despite

otherwise normal cardiac evaluation. Current guidelines do not address the need for/frequency of repeat testing in asymptomatic individuals with TTR gene mutations or extra-cardiac TTR deposits. Early identification with repeat testing may facilitate presymptomatic initiation of therapy to halt disease progression. This case highlights the importance of follow-up <sup>99m</sup>Tc-PYP scanning in these patients.

## **Supplementary material**

Supplementary material is available at European Heart Journal - Case Reports online.

**Consent:** The author/s confirm that written consent for submission and publication of this case report including image(s) and associated text has been obtained from the patient in line with COPE guidance.